Basic Information
| LncRNA/CircRNA Name | MA-LINC1 |
| Synonyms | LINC01024, MA-linc1 |
| Region | GRCh38_5:140072857-140108630 |
| Ensemble | ENSG00000245146 |
| Refseq | NR_102739 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, RNAi, Western blot etc. |
| Sample | cell lines (U2OS, SAOS-2) |
| Expression Pattern | up-regulated |
| Function Description | We employed qPCR to analyze MA-linc1 levels in four cell lines: U2OS and H1299 cells, as well as the human embryonic lung fibroblasts, WI38, and another human osteosarcoma cell line, SAOS-2, each expressing the conditionally active E2F1. This analysis demonstrated that activation of the ectopic E2F1 resulted in a significant increase in MA-linc1 RNA levels in all four cell lines. |
| Pubmed ID | 26337085 |
| Year | 2015 |
| Title | A novel mitosis-associated lncRNA, MA-linc1, is required for cell cycle progression and sensitizes cancer cells to Paclitaxel. |
External Links
| Links for MA-LINC1 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |